Articles

Biopharma M&A Trends: Resilience Amidst Large Deal Decline

Despite a noticeable decline in large biopharma mergers and acquisitions, the overall M&A landscape remains robust. This article explores the implications for business development teams and investors.

Global Preparedness: Lessons from Hantavirus and Ebola Outbreaks

This article examines the implications of recent hantavirus and Ebola outbreaks on global health preparedness and the pharmaceutical sector.

Takeda Settles Kickback Allegations: What It Means for Pharma

Takeda has agreed to a $13.6 million settlement regarding allegations of kickbacks to doctors. This article explores the implications for the pharmaceutical sector.

Latest Comings and Goings in Pharma Leadership

This article covers recent leadership transitions in the pharmaceutical sector, highlighting their potential impacts on business strategies and market dynamics.

Supreme Court Ruling on Mifepristone: Implications for Pharma

The Supreme Court's decision to preserve access to mifepristone by mail has significant implications for the pharmaceutical sector, particularly in abortion care.

Aardvark's Next Move After Clinical Hold: Alumis' Verdict on Acelyrin

This article explores Aardvark's strategic decisions following a clinical hold and Alumis' evaluation of the Acelyrin asset, highlighting implications for the pharmaceutical industry.

#ASGCT26: Zillow-like Marketplace for Abandoned Gene Therapies

A new marketplace for abandoned gene therapies has launched, drawing parallels to Zillow. This article explores its implications for the pharmaceutical industry.

Amgen's Expanded Crackdown on 340B Program Misuse

Amgen has intensified its efforts to address what it claims is the misuse of the 340B program. This article explores the implications for the pharmaceutical sector.

Post-Hoc Live: Makary's Departure from FDA and Future Implications

This article examines the recent departure of Makary from the FDA and its potential impact on the pharmaceutical landscape.

New Ebola Outbreak in Congo: Implications for Pharma

A new Ebola outbreak has been confirmed in a remote province of Congo, resulting in 65 deaths. This article explores the implications for pharmaceutical companies.

M&A Trends: Mid-Size Pharma Companies on the Rise

Mid-size pharmaceutical companies are stepping up their M&A activities, challenging the dominance of big pharma. This article explores the implications for business development teams and investors.

U.S. Pressure on Germany's Drug Prices: Implications for Pharma

This article delves into the U.S. government's pressure on Germany to lower drug prices, the FDA's recent upheaval, and the status of biotech clinical trials.

Eisai's Leqembi Sales Forecast: A Closer Look at $900M Potential

Eisai is making strides toward achieving blockbuster status for Leqembi, with a projected sales forecast of $900M. This article explores the implications for the pharmaceutical landscape.

Get Ready for ISPOR 2026 International: Key Insights and Trends

ISPOR 2026 International is set to be a pivotal event for pharma professionals. Join us as we explore key insights and trends to watch.

CDER Chief Høeg Fired: Implications for Pharma Industry

The firing of CDER Chief Høeg from the FDA raises questions about leadership stability and its effects on the pharmaceutical industry. This article explores the implications for pharma teams and investors.

Political Contest in the U.K. Could Shake Up Drug Pricing

The ongoing political contest in the U.K. has significant implications for drug pricing. This article explores the potential impacts on the pharmaceutical industry.

Holland & Knight Health Dose: Oncology Updates from May 12, 2026

This article provides a comprehensive analysis of the latest updates in oncology from the Holland & Knight Health Dose on May 12, 2026. Key insights for BD teams, investors, and analysts are highlighted.

Biotech Leaders Push for Pazdur Amid Takeda Layoffs

Biotech leaders are rallying for Pazdur's approval while Takeda announces significant layoffs. This article explores the implications for the pharma industry.

NICE Approval for Imfinzi: Implications for Stomach Cancer Treatment

NICE's backing of Imfinzi for stomach cancer marks a significant milestone for AstraZeneca. This article explores the implications for investors and pharma teams.

US Cancer Clinics Rush for Revolution Medicines' New Pancreatic Cancer Drug

US cancer clinics are responding rapidly to the approval of Revolution Medicines' experimental drug for pancreatic cancer. This article explores the implications for stakeholders.